Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 5.1% – Still a Buy?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was up 5.1% on Friday. The stock traded as high as $3.57 and last traded at $3.32. 274,438 shares changed hands during trading, a decline of 27% from the average session volume of 376,538 shares. The stock had previously closed at $3.16.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Up 5.1%

The business’s fifty day moving average is $2.76 and its 200-day moving average is $2.30. The company has a market cap of $442.36 million, a PE ratio of -0.52 and a beta of 0.96.

Indaptus Therapeutics (NASDAQ:INDP) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the body’s immune system to fight cancer and other serious diseases. The company’s approach is based on using attenuated or inactivated bacterial agents to activate multiple components of the immune response.

Indaptus’ lead product candidate is Decoy20, an investigational, systemically administered bacterial immunotherapy. The treatment is designed to engage innate and adaptive immune pathways and potentially improve the body’s ability to recognize and attack tumor cells.